Axogen [AXGN] vs Abbott Laboratories [ABT] Detailed Stock Comparison

Axogen Inc.

NASDAQ
Loading...

Abbott Laboratories

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Axogen Inc. wins in 2 metrics, Abbott Laboratories wins in 16 metrics, with 0 ties. Abbott Laboratories appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Axogen Inc. Abbott Laboratories Better
P/E Ratio (TTM) -110.18 25.97 Abbott Laboratories
Price-to-Book Ratio 13.15 3.09 Abbott Laboratories
Debt-to-Equity Ratio 55.50 26.79 Abbott Laboratories
PEG Ratio 0.04 -1.41 Axogen Inc.
EV/EBITDA -2,165.44 13.74 Abbott Laboratories
Profit Margin (TTM) -6.97% 13.90% Abbott Laboratories
Operating Margin (TTM) -16.31% 16.50% Abbott Laboratories
EBITDA Margin (TTM) N/A 16.50% N/A
Return on Equity -13.49% 12.36% Abbott Laboratories
Return on Assets (TTM) -2.31% 7.52% Abbott Laboratories
Free Cash Flow (TTM) $-4.78M $7.40B Abbott Laboratories
Dividend Yield N/A 1.97% N/A
1-Year Return 341.03% -34.98% Axogen Inc.
Price-to-Sales Ratio (TTM) 8.27 3.57 Abbott Laboratories
Enterprise Value $1.89B $166.96B Abbott Laboratories
EV/Revenue Ratio 8.40 3.70 Abbott Laboratories
Gross Profit Margin (TTM) 74.13% N/A N/A
Revenue per Share (TTM) $5 $26 Abbott Laboratories
Earnings per Share (Diluted) $-0.34 $3.57 Abbott Laboratories
Beta (Stock Volatility) 0.98 0.78 Abbott Laboratories
Short % of Float 6.92% 1.53% Abbott Laboratories

Axogen Inc. vs Abbott Laboratories Stock Performance Analysis

Loading Price Chart...

AXGN
ABT

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Axogen Inc.1.72%5.50%6.71%33.19%46.88%41.10%
Abbott Laboratories0.56%-2.02%4.97%-19.35%-30.98%-28.60%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Axogen Inc.341.03%367.90%106.53%628.81%1,769.57%12,185.71%
Abbott Laboratories-34.98%-16.97%-20.08%135.84%255.56%329.52%

Performance & Financial Health Analysis: Axogen Inc. vs Abbott Laboratories

MetricAXGNABT
Market Information
Market Cap i$1.94B$160.70B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i1,245,23813,495,583
90 Day Avg. Volume i1,068,35312,934,461
Last Close$43.74$88.67
52 Week Range$9.22 - $45.83$81.97 - $139.06
% from 52W High-4.56%-36.24%
All-Time High$56.85 (Jul 23, 2018)$142.60 (Dec 27, 2021)
% from All-Time High-23.06%-37.82%
Growth Metrics
Quarterly Revenue Growth0.21%0.08%
Quarterly Earnings Growth0.21%-0.19%
Financial Health
Profit Margin (TTM) i-0.07%0.14%
Operating Margin (TTM) i-0.16%0.17%
Return on Equity (TTM) i-0.13%0.12%
Debt to Equity (MRQ) i55.5026.79
Cash & Liquidity
Book Value per Share (MRQ)$2.73$30.02
Cash per Share (MRQ)$0.80$5.14
Operating Cash Flow (TTM) i$812,000$10.80B
Levered Free Cash Flow (TTM) i$3.58M$13.77B
Dividends
Last 12-Month Dividend Yield iN/A1.97%
Last 12-Month Dividend i$0.00$2.40

Valuation & Enterprise Metrics Analysis: Axogen Inc. vs Abbott Laboratories

MetricAXGN (Apr 24, 2026)ABT (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-110.1825.97
Forward P/E i47.3115.29
PEG Ratio i0.04-1.41
Price to Sales (TTM) i8.273.57
Price to Book (MRQ) i13.153.09
Market Capitalization
Market Capitalization i$1.94B$160.70B
Enterprise Value i$1.89B$166.96B
Enterprise Value Metrics
Enterprise to Revenue i8.403.70
Enterprise to EBITDA i-2,165.4413.74
Risk & Other Metrics
Beta i0.980.78
Book Value per Share (MRQ) i$2.73$30.02

Financial Statements Comparison: Axogen Inc. vs Abbott Laboratories

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricAXGN (2025)ABT (2025)
Revenue/Sales i225.21M44.33B
Cost of Goods Sold i57.86M19.32B
COGS % of Revenue i25.7%43.6%
Gross Profit i167.35M25.01B
Gross Margin i74.3%56.4%
Research & Development i32.89M2.94B
Operating Income (EBIT) i-7.85M8.05B
Operating Margin i-3.5%18.2%
EBITDA i826,00012.03B
EBITDA Margin i0.4%27.1%
Pre-Tax Income i-15.70M8.47B
Pre-Tax Income % of Revenue i-7.0%19.1%
Income Tax iN/A1.94B
Income Tax % of Revenue i0.0%4.4%
Net Income (Profit) i-15.70M6.52B
Profit Margin i-7.0%14.7%

Balance Sheet & Liquidity Metrics

MetricAXGN (2025)ABT (2025)
Cash & Equivalents i35.55M8.52B
Total Current Assets i120.42M26.00B
Total Current Assets % of Revenue i53.5%58.6%
Total Current Liabilities i23.56M16.50B
Total Current Liabilities % of Revenue i10.5%37.2%
Long-Term Debt i65.26M10.83B
Long-Term Debt % of Revenue i29.0%24.4%
Total Shareholders Equity i128.85M52.77B
Retained Earnings i-306.96M49.78B
Retained Earnings % of Revenue i-136.3%112.3%
Property, Plant & Equipment i29.38M17.57B

Cash Flow Statement Comparison

MetricAXGN (2025)ABT (2025)
Operating Cash Flow i10.26M10.80B
Operating Cash Flow % of Revenue i4.6%24.4%
Capital Expenditures i-3.75M-2.17B
Free Cash Flow i-4.78M7.40B
FCF Margin i-2.1%16.7%
Debt Repayment i-32,000-1.50B
Common Stock Repurchase iN/A-893.00M

Short Interest & Institutional Ownership Analysis

MetricAXGNABT
Shares Short i3.50M23.83M
Short Ratio i4.041.93
Short % of Float i6.92%1.53%
Shares Outstanding i47.20M1.74B
Float Shares i50.75M1.73B
% Held by Insiders i2.12%0.54%
% Held by Institutions i88.11%82.23%
% Held by Public i9.77%17.23%

Dividend Analysis & Yield Comparison: Axogen Inc. vs Abbott Laboratories

MetricAXGNABT
Last 12-Month Dividend i$0.00$2.40
Last 12-Month Dividend Yield iN/A1.97%
3-Year Avg Annual Dividend i$0.00$2.24
3-Year Avg Dividend Yield iN/A0.50%
3-Year Total Dividends i$0.00$6.72
Ex-Dividend DateN/AJan 15, 2026